FTC Finds Pay-For-Delay Deals At Lowest Level In 15 Years

By Rachel Cohrs / May 23, 2019 at 5:58 PM
The Federal Trade Commission said on Thursday (May 23) that while brand and generic drug makers settled patent disputes more often in fiscal year 2016 than prior years, only one of the agreements met the Supreme Court’s criteria of potentially being anticompetitive. The generic drug lobby seized on the finding to urge lawmakers to back away from plans to ban such settlements. The House recently passed a bill addressing pay-for-delay settlements in a package pairing drug-pricing bills with measures to...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.